Many new products are available for the 2023-2024 Respiratory Syncytial Virus (RSV) season that have been approved by the Food and Drug Administration (FDA) and recommended by the Center for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP). For details on the 2023-2024 recommendations, please refer to CDC RSV ACIP Vaccine Recommendations.

The following information has been updated replaces the NC Medicaid Respiratory Syncytial Virus (RSV) Guidelines for 2023-2024 bulletin published October 5, 2023:

  • Addition of new American Medical Association codes for the administration of Beyfortus.
  • Clarification on the use of the COVID-19 Counseling code in light of new AMA codes.
  • Clarification on the billing of Abrysvo in the office or in the pharmacy.
  • Clarification of managed care coverage of pharmacy claims for Abrysvo and Arexvy.
  • Addition of immunization billing guidance for Federally Qualified Health Centers (FQHC) and Rural Health Clinics (RHC).
  • Addition of information on the limited availability of nirsevimab (Beyfortus).

View more information on these updates here.